ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Vertex in long-term reimbursement agreement with ROI for CF medicines
June 12, 2017Vertex Pharmaceuticals has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund Orkambi (lumacaftor/ivacaftor) for all of the approximately 500 people in Ireland with cystic fibrosis (CF) ages 12 and older who ha -
Vertex to acquire Concert Pharmaceuticals’ cystic fibrosis drug for $250m
March 08, 2017US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m. -
Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis
March 08, 2017Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF.
Pharma Sources Insight January 2025
